Neuro-oncology

Content

 

Introduction

The Laboratory of Molecular Neurooncology is located at the Department of Neurology of the University Hospital Zurich (Frauenklinikstrasse 26, CH-8091 Zurich). The Laboratory is led by Prof. Dr. M. Weller together with Prof. Dr. P. Roth, and Dr. M. Silginer (organisational chart).

Major research areas of the laboratory include cancer immunology and immunotherapy, mechanisms of migration, invasion and angiogenesis, and resistance to therapy in brain tumors.

Major goals of our cancer immunology research include the characterization of immunological characteristics of glioma cells, in particular the putative tumor stem cells. We are also exploring transforming growth factor beta (TGF-beta)-mediated pathways and TGF-beta-targeting therapeutics. We seek to develop translational research concepts regarding the immunogenicity of glioma cells, immunocytokines and immune checkpoint inhibition. The Clinical Research Priority Program (CRPP) "ImmunoCure" represents an interdisciplinary consortium of research groups exploring novel immunotherapeutic approaches with the focus on chimeric antigen receptor (CAR)-T cells as targeted immunotherapeutic strategy. In addition, we perform extensive studies on the primary and acquired resistance of glioma cells to radiotherapy and chemotherapy. In cooperation with the Department of Neurosurgery (Prof. Dr. L. Regli), a tumor bank with tumor tissue for histology and molecular analyses as well as for the isolation and characterization of tumor-derived glioma stem cells has been established.

Methods employed include fluorescence tomography for in vivo imaging in our preclinical models, flow cytometry and in the framework of cooperations two-photon microscopy and positron emission tomography.

In the area of clinical neurooncology, we founded, together with the partner institutions of neuroradiology, neurosurgery, nuclear medicine, neuropathology, radiation oncology, medical oncology and pediatric neurooncology, the Brain Tumor Center Zurich at the Cancer Center Zurich in January 2012.

In cooperation with the Centers of the German Glioma Network (www.gliomnetzwerk.de) and the European Organization for Research and Treatment of Cancer (EORTC), we are involved in several clinical pathological molecular correlative projects looking at, e.g. prognostic and predictive value of molecular markers such as 1p 19q codeletion, MGMT promotor methylation and isocitrate dehydrogenase mutations in different glioma entities and long-time survival in glioblastoma.
  
The laboratory has been supported by the Brain Tumor Funder Collaborative of the US, Swiss National Science Foundation, Oncosuisse, the Zurich Cancer League, the Wilhelm Sander-Foundation, the EMDO Foundation, the Hartmann-Müller Foundation, the Koetser Foundation, the Sophien Foundation, the foundation “Stiftung für Angewandte Krebsforschung” and the German Research Foundation and performs cooperative research projects with the pharmaceutical companies  Apogenics (Heidelberg), Novocure (Jersey Isle), Philogen (Siena) und Quercis (Zug).


Address 

Department of Neurology and Laboratory for Molecular Neuro-Oncology
University Hospital Zurich
Frauenklinikstrasse 26
8091 Zurich
Switzerland


Team

Please click here to see the structural organisation chart.

You will find the list of group members on the following page.

Please click here to see the organisation chart of the laboratory teams.

 

Scientific projects

Selected scientific projects are listed in the table below. A complete overview and description of current and completed projects are listed on the website of the "Forschungsdatenbank" of the University of Zurich.


Current scientific projects

Funding source
Applicants
Titel
Duration

​Schweizerischer Nationalfond (SNF)

​M. Weller

​The role of interferon type I signalling in the malignant phenotype and response to immune checkpoint inhibition in glioblastoma

​07/2019 - 06/2022

​Sophienstiftung

​​M. Weller

TERT promoter mutation: a novel predictive biomarker in gliolastoma?

​01/2019 - 12/2022

​Novel combinations of immunotherapy and radiotherapy for the treatment of primary and secondary brain tumors

01/2020 - 12/2023

Stiftung für angewandte Krebsforschung

​A novel integrative approach to characterize and exploit the proteomic landscape in metastatic lung cancer

​01/2020 - 12/2022

Klinischer Forschungs-schwerpunkt (KFSP)

​P. Roth
M.G. Manz(Hematology)

​ImmunoCure

​01/2019 - 12/2021

​Oncosuisse / Swiss Cancer League

​P. Roth
T. Weiss

lntegrins as targets for advanced chimeric antigen receptor (CAR) T cell treatment of glioblastoma

​04/2019 - 03/2022

Desirée and Niels Yde Foundation

H.-G. Wirsching

Evolution of the genomic-immunologic landscape of glioblastoma under chemoradiotherapy

01/2019 - 12/2021

 

Current clinical trials

Title
Principal Investi­gator
Indication
Contact in Zurich
Status
​EORTC 1608-BTG, Phase Ib


TGO2 in elderly newly diagnosed or adult relapsed patients with anaplastic astrocytoma or glioblastoma

​Prof. Dr. M. Weller,
Zürich

Arm A and B: Newly diagnosed anaplastic astrocytoma or glioblastoma (>65 years)

Arm C: Recurrent anaplastic astrocytoma or glioblastoma (>18 years)

​Prof. Dr. P. Roth

recruiting (Arm A and B)
completed (Arm C)

EORTC 1635, Phase III


IDH mutated 1p/19q intact lower grade glioma following resection: Wait Or Treat? IWOT - A phase III study

EORTC​

​IDH mutated 1p/19q intact lower grade glioma

​Prof. Dr. M. Weller

​​recruiting

​PERGOLA, Phase II

Pembrolizumab for newly diagnosed glioblastoma: a prospective, open-label, single-arm, multicenter phase II study

​Prof. Dr. P. Roth

​Newly-diagnosed glioblastoma

Prof. Dr. P. Roth

​recruiting

CheckMate 548, phase III

Study of temozolomide plus radiation therapy with nivolumab or placebo, for newly diagnosed patients with glioblastoma

​Bristol-Myers Squibb,
Prof. Dr. P. Roth

​Newly diagnosed glioblastoma, methylated MGMT promotor

​Prof. Dr. P. Roth

​​completed

EORTC-1709-BTG, Phase III


Multicenter study of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma

​Prof. Dr. P. Roth

​Newly diagnosed glioblastoma

​Prof. Dr. P. Roth

​recruiting

Gliosun, phase I/II


A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein

​Philogen

​Newly diagnosed glioblastoma

​Dr. T. Weiss

​recruiting

Gliomoon, phase I/II

A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF in patients with IDH wildtype WHO grade III /IV glioma at first relapse

Philogen

​IDH wildtype WHO grade III /

IV glioma at first relapse

​Dr. T. Weiss

​recruiting

Agios AG881-C-004, phase III

Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

​Agios Pharmaceuticals

​Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

​Prof. Dr. P. Roth

​recruiting

BLZ945, PDR001, phase II

BLZ945 single agent or BLZ945 in combination with PDR001 in patients with recurrent isocitrate dehydrogenase (IDH) wild-type glioblastoma

​Novartis,
Prof. Dr. M. Weller

​Recurrent glioblastoma

​Prof. Dr. M. Weller

​​recruiting

​EORTC 1308 ROAM

Radiation versus observation following surgical resection of atypical meningioma

​EORTC, Prof. Dr. N. Andratschke

​newly diagnosed atypical meningeoma (WHO grade II)

​Prof. Dr. N. Andratschke

​recruiting

CDI-CS-003, phase I/IIa

BAL101553 in patients with advanced solid tumors or recurrent glioblastoma

​Basilea,
Prof. Dr. P. Roth  

​Recurrent glioblastoma

​​Prof. Dr. P. Roth

​recruiting

BGB-290-104, phase I/IIa


Multicenter study to assess the safety, tolerability
and efficacy of BGB-290 in combination with radiation
therapy and/or temozolomide in patients with newly diagnosed
or recurrent glioblastoma

​BeiGene,
Prof. Dr. M. Weller 

​Newly diagnosed glioblastoma, unmethylated MGMT promotor or recurrent glioblastoma

​Prof. Dr. M. Weller
Dr. K. Seystahl
Dr. H.G. Wirsching

​recruiting

​GLIODRIVE

Fitness to drive for Glioblastoma patients after standard therapy

​Dr. S. Hofer

​Glioblastoma patients, without tumor progression after standard therapy or 6 months after diagnosis and without history of seizures within the last 12 months

​Dr. S. Hofer

​recruiting

IOSI-RTO-001, phase II

Stereotactic Radiosurgery or Hypofractionated ImageGuided Radiotherapy to the surgical cavity after resection of brain metastases: a multicenter, single arm, open-label trial

Istituto Oncologico della Svizzera Italiana (IOSI), Dr. med. Gianfranco A. Pesce

Patients after surgical resection of a single brain metastasis (primary tumor: lung, breast, melanoma, kidney, colorectal cancer) or single cases of surgical resected brain metastasis and another not resected lesion

Prof. Dr. N. Andratschke

​recruiting

ReSurge, Phase II

Randomized Controlled Comparative Phase II Trial on Surgery for Glioblastoma Recurrence

A. Raabe, Bern

Recurrent glioblastoma;
complete removal of contrast-enhancing lesion considered feasible

Prof. Dr. L. Regli

recruiting


Completed PhD research projects

Completed projects of PhD students of our laboratory are listed below. Related publications can be found by the following link

Name
 
Projekt
Start
End

Silginer

Manuela

Integrin inhibition interferes with TGF-beta signaling in malignant glioma cells

2010-01

2013-10

Ahmad

Mushfika

How stem-like are sphere cultures from long-term cancer cell lines?

2010-08

2013-11

Codo

Paula

Growth and differentiation factor (GDF)-15, microRNA and the immunophenotype of glioblastoma

2011-02

2014-09

Stojceva

Nina

TMZ resistance in glioblastoma

2012-01

2015-06

Shanmugarajan

Krishnan

Modulation of cerebral endothelial cell function by Glioma-Derived factors

2012-10

2016-04

Schroeder

Judith

The Role of TGF-β Coreceptors in Glioblastoma

2012-10

2015-09

Mangani

Davide

Co-inhibition of the TGF-β and VEGF pathways in glioblastoma

2013-01

2017-06

Papa

Eleanna

Crosstalk between the Met and TGF-β pathways in glioblastoma

2013-01

2017-06

Papachristodoulou

Alexandros

Focused ultrasound-mediated delivery of encapsulated MGMT antagonists for the treatment of temozolomide-resistant glioblastoma

2013-01

2017-05

Ventura

Elisa

Extracellular control of TGF-beta signaling in glioblastoma

2013-01

2017-06

von Achenbach

Caroline

Growth factor signalling in glioblastoma

2015-02

2018-09

Lohmann

Birthe

Modulation of glioblastoma biology by type I interferons

2015-01

2018-09

Weiss

Tobias

Characterisation and exploitation of the NKG2D system in glioblastoma

2015-09

2019-04


Publications

Please follow the link to the detailed list of publications here.


Donations


Donations for our scientific work can be made via bank transfer to either of the following accounts:
Transfer to our postal giro account: Recipient: Rechnungswesen der Universität Zürich 8001 Zürich, giro account no.: 80-643-0, IBAN: CH46 0900 0000 8000 0643 0, BIC: POFICHBEXXX
 
Transfer to our bank account: Recipient: Universität Zürich CH-8001 Zürich, account no. 1100-0109.594 (BC 700) - Zürcher Kantonalbank, CH-8010 Zürich, Swift-Code: ZKBKCHZZ80A, IBAN: CH51 0070 0110 0001 0959 4

For accounting purposes we would like to ask you to add the "payable to" notice as follows: "Zu Gunsten des Kontos F-86001-01-01". If you want to choose the intended purpose in detail, please contact us before or after your bank transfer (tel. +41 44 255 55 00). We will be pleased to send you an official confirmation of your donation by simply contacting us via our telephone number +41 44 255 55 00.


Links
  


We use cookies to make our website user-friendly, to continuously improve it and to analyze the traffic of our website. By continuing to browse the site, you are agreeing to our use of cookies. Further information can be found in our privacy policy.